8 News & Press Releases found

Intrommune Therapeutics news

Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy

Observed only mild and transient adverse events, with no use of emergency epinephrine

Observed 98.4% patient compliance to date with novel OMIT therapeutic modality

Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) --

Oct. 26, 2022

Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with pean

Jun. 22, 2022

Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory.

“Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant working with our regulatory and clinical development teams,” said Michael Nelson, CEO

Jun. 1, 2022

INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy

Apr. 6, 2022

Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy

NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. INT301 is a novel peanut desensitization immunotherapy formulated as a fully-functioning toothpaste and conveniently administered during a patient’s daily toothb

Feb. 8, 2022